XNAS
ENTO
Market cap913kUSD
Jun 03, Last price
0.45USD
1D
2.45%
1Q
-20.15%
IPO
-84.87%
Name
First Wave BioPharma Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
114.82%
Rev. gr., 5y
%
Revenues
0k
Net income
-16m
L-4.74%
CFO
-9m
L-25.53%
Profile
AzurRx BioPharma, Inc. engages in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. The company is headquartered in Brooklyn, New York and currently employs 12 full-time employees. The firm is engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal (GI) disorders. The firm's product pipeline consists of two therapeutic proteins, such as MS1819 and AZX1101. MS1819 is an acid-resistant secreted lipase produced by Yarrowia lipolytica, known as LIP2, that the Company is developing through recombinant deoxyribonucleic acid (DNA) technology for the treatment of exocrine pancreatic insufficiency (EPI), associated with chronic pancreatitis (CP) and cystic fibrosis (CF). AZX1101 is a recombinant-lactamase combination of bacterial origin under development for the prevention of hospital-acquired infections by resistant bacterial strains induced by parenteral administration of b-lactam antibiotics (known as nosocomial infections), as well as the prevention of antibiotic-associated diarrhea (AAD).
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | 15,800 | 12,784 | ||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | (15,800) | (12,784) | ||||||||
NOPBT Margin | ||||||||||
Operating Taxes | 1,952 | |||||||||
Tax Rate | ||||||||||
NOPAT | (15,800) | (14,736) | ||||||||
Net income | (15,795) -4.74% | (16,581) -71.93% | ||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | 6,226 | 15,830 | 23,296 | |||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | 82 | 680 | 670 | |||||||
Long-term debt | 200 | 361 | 494 | |||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | 118 | (2,692) | (221) | |||||||
| Cash flow | ||||||||||
Cash from operating activities | (9,218) | (12,378) | (22,344) | |||||||
CAPEX | (500) | |||||||||
Cash from investing activities | 88 | (500) | ||||||||
Cash from financing activities | 5,581 | 15,227 | 15,740 | |||||||
FCF | (55,767) | (15,471) | 1,176,241,553 | |||||||
| Balance | ||||||||||
Cash | 163 | 3,712 | 1,363 | |||||||
Long term investments | 22 | 22 | ||||||||
Excess cash | 163 | 3,733 | 1,384 | |||||||
Stockholders' equity | (140,706) | (184,329) | (168,534) | |||||||
Invested Capital | 198,651 | 188,758 | 172,159 | |||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | 336 | 36 | ||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | 49 | (15,771) | (12,755) | |||||||
EV/EBITDA | ||||||||||
Interest | 22 | 16 | ||||||||
Interest/NOPBT | ||||||||||